Please login to the form below

Ionis

This page shows the latest Ionis news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.

Latest news

Merck strengthens KRAS stake with Taiho and Astex partnership

Other competitors in the KRAS inhibitor race include Mirati, Boehringer Ingelheim, Johnson &Johnson/Wellspring and AstraZeneca/Ionis.
Biogen bets on Ionis’ early-stage Alzheimer’s drug

payout. . The drug – IONIS-MAPTRx – is an antisense therapy designed to reduce production of microtubule-associated protein tau (MAPT) or tau in the central nervous system. ... In pre-clinical research, IONIS-MAPTRx demonstrated prevention of
Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

Has potential in cardiovascular and metabolic diseases. Pfizer has bolted on an antisense drug with potential in cardiovascular and metabolic diseases to its pipeline via a licensing deal with Ionis’ Akcea ... Founded in 2015, Akcea spun out of Ionis
Biogen’s R&D chief Ehlers heads for the exit

There’s still plenty in the neuroscience pipeline however, including tofersen for amyotrophic lateral sclerosis (ALS) which stems from an alliance with antisense specialist Ionis and is due for a phase
Amgen reveals more data on KRAS drug

race, which include Mirati, Boehringer Ingelheim, Johnson &Johnson/Wellspring, Merck/Moderna and AstraZeneca/Ionis.

More from news
Approximately 16 fully matching, plus 32 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma leaders to watch in 2020

Standing in its way is a similarly priced antisense rival from Ionis and Akcea – Tegsedi (inotersen) – as well as Pfizer’s fast- growing Vyndaqel/Vyndamax (tafamidis), which is approved for hATTR
Where next in Alzheimer’s disease R&D?

The big biotech is testing its own BIIB092 in early Alzheimer’s patients and has an option to develop an Ionis Pharmaceuticals’ antisense drug designed to reduce production of tau in
Deal Watch October 2018

Joint development using SQZ’s cell therapy. platform. $1.375B. Option. Ionis. RNA‐targeted therapeutics for complement mediated. ... RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

While Onpattro has outshone Ionis’ product in safety and efficacy, analysts see Onpattro’s lack of cardiovascular claims in its US label as a weak point. ... England’s NICE is just beginning its review of Onpattro (in tandem with a review of
The European Medicines Agency: PRIME’d for access?

Since March 2018 Roche, with Ionis, have added another PRIME drug to their portfolio. ... RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

The big issue: Whether you want to lead or follow, you need to understand the elephant in the C-suite...
INFOGRAPHIC 02: The Importance of clinical study websites: Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
Working with, Advocating for, and Empowering Patients: A holistic view of how to work with patients virtually...